Latest Breaking News On - Homozygous familial hypercholesterolaemia - Page 9 : comparemela.com

Amryt Pharma PLC (AIM:AMYT) | RNS | Result of General Meetings

Amryt Pharma PLC (AIM:AMYT) | RNS | Result of General Meetings
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBen maddisonAmber fennellRory nealonHypercholesterolaemia hoJohn moreJoe wileyEdward mansfieldDaniel bushTim mccarthyLifesci advisorsCompany secretarySecurities exchangeChiasma incAmryt investor relations department

Amryt Pharma Holdings Ltd (via Public) / Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc , and posting of Annual Report and Notices of General Meetings DUBLIN, Ireland, and Boston MA, 28 June 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases (the Company or Amryt ), is pleased to announce that: Copies of the Circular and the Company s annual report for the 12 months ended 31 December 2020, and the notice for each of the General Meetings, when posted, will also be available on the Company s website, www amrytpharma com The Company continues to closely monitor the evolving situation in respect of COVID-19 The health and welfare of our shareholders and colleagues is our priority in making arrangements for the General Meetings Given the UK and Irish Governments ongoing guidance on social distancing, non-essential travel and public gatherings relating to the COVID-19 pandemic which we believe would significantly impact the ability of our shareholders to attend the General Meetings, and in the interests of maintaining the health, safety and welfare of our shareholders and colleagues, as well as the public in general, it is currently intended that the General Meetings will be closed meetings and that it will not be possible for our shareholders to attend the General Meetings The General Meetings will take place at the times, date and venue stated above but it is currently intended that the General Meetings will only be attended by the minimum number of persons legally required to attend in order for the meeting to be quorate (which will be facilitated by the attendance of certain Directors and/or the Company Secretary) The Directors have decided to hold the General Meetings at the Company s headquarters in Dublin, Ireland, to enable such persons to be present and provide for a quorum Any other shareholder who attempts to attend in person will currently be refused entry Shareho

are not approved . Telephone Facility - To support engagement with our shareholders in these exceptional circumstances, a telephone facility will be provided to allow shareholders to listen to the business of the General Meetings. If you wish to listen live to the proceedings of the General Meetings, you will be able to do so by dialling the following relevant number at the commencement time of the meeting: Passcode: 6597393 UK: +44 (0) 203 009 5709 Ireland: +353 (0) 1 506 0626 Any such shareholder participation via the telephone facility will not constitute formal attendance at the General Meetings. Shareholders using the telephone facility should also submit their Form of Proxy by the relevant deadline in advance of the General Meetings, as Shareholders will not be able to vote using the telephone facility.

United kingdomUnited statesAmber fennellRory nealonHypercholesterolaemia hoAmryt adssDuff phelpsJoe wileyEdward mansfieldTim mccarthyLifesci advisorsCompany or amrytChiasma incTorreya capitalFinancial servicesDunn crutcher

Amryt Pharma PLC (AIM:AMYT) | RNS | Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with I

Amryt Pharma PLC (AIM:AMYT) | RNS | Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with I
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAmber fennellRory nealonHypercholesterolaemia hoAmryt adssJohn moreJoe wileyEdward mansfieldDaniel bushTim mccarthyLifesci advisorsChiasma incFinancial servicesExchange commissionIts proposed acquisition of chiasma inc

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

United kingdomUnited statesAmber fennellRory nealonHypercholesterolaemia hoStifel ben maddisonAmryt pharmaJohn moreJoe wileyEdward mansfieldDaniel bushTim mccarthyLifesci advisorsCompany secretaryDrug administrationConsilium strategic communications

Amryt Pharma PLC (AIM:AMYT) | RNS | FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolys

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa PDUFA date of DUBLIN, Ireland, and Boston MA, June 3, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has granted Priority Review for Amryt’s New Drug Application (“NDA”) for Oleogel-S10 for the treatment of Epidermolysis Bullosa (“EB”). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.

United kingdomUnited statesBen maddisonAmber fennellRory nealonHypercholesterolaemia hoAmryt pharmaJohn moreJoe wileyEdward mansfieldDaniel bushTim mccarthyLifesci advisorsCompany secretaryDrug administrationConsilium strategic communications